2-[2-(5-Cyano-3-hydroxy-4-methyl-pyridin-2-yl)-thiazol-4-yl]-N-(2-pyridin-2-yl-ethyl)-acetamide | 1208072-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[2-(5-Cyano-3-hydroxy-4-methyl-pyridin-2-yl)-thiazol-4-yl]-N-(2-pyridin-2-yl-ethyl)-acetamide
• 英文别名: 2-[2-(5-cyano-3-hydroxy-4-methylpyridin-2-yl)-1,3-thiazol-4-yl]-N-(2-pyridin-2-ylethyl)acetamide
• CAS: 1208072-95-0
• 化学式: C₁₉H₁₇N₅O₂S
• 分子量: 379.442
• InChiKey: MNKLNTMHRWFUOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-bromo-4-methyl-3-nitropicolinonitrile 在 四(三苯基膦)钯 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 水 、 sodium methylate 、 二硫代磷酸二乙酯 、 三乙胺 、 sodium hydroxide 、 lithium iodide 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.92h， 生成 2-[2-(5-Cyano-3-hydroxy-4-methyl-pyridin-2-yl)-thiazol-4-yl]-N-(2-pyridin-2-yl-ethyl)-acetamide
  参考文献：
  名称：

  Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

  摘要：

  The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were developed for the preparation of their analogs containing the new scaffolds. In addition, the structure-activity relationship (SAR) of the 2-[2-(3-hydroxy-pyridin-2yl)-thiazol-4-yl]-acetamide derivatives and their biological activities were reported. The complex structure of compound 18 with PHD2 was also obtained for the purpose of more efficient lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.003

文献信息

• [EN] PHENOL DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PHÉNOL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CRYSTALGENOMICS INC

  公开号：WO2010018458A2

  公开（公告）日：2010-02-18

  Disclosed herein are hydroxyaryl or hydroxyheteroaryl derivative compounds, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIFα in a subject, modulating expression of HIF-regulated genes in a subject, treating an HIF -related disorder in a subject, increasing levels of endogenous EPO in a subject, or treating a disorder in a subject, using the disclosed compounds.